Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xtant Medical Holdings, Inc. (XTNT) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports, proxy statements, and financial updates filed with the U.S. Securities and Exchange Commission. Xtant is a global medical technology company focused on orthobiologics for chronic and surgical wound care and sports medicine markets, as well as spinal implant systems for spinal and other orthopedic conditions, and its filings offer detailed insight into how this business is governed and financed.
Among the key documents available are Form 8-K current reports, where Xtant discloses material events. For example, an 8-K dated December 3, 2025 describes the completion of the sale of certain Coflex and CoFix spinal implant assets and all shares of Paradigm Spine GmbH, its international hardware business, to Companion Spine entities, along with related use of proceeds and pro forma financial information. Other 8-Ks report quarterly financial results, the use of non-GAAP adjusted EBITDA, changes to the Board of Directors, the establishment of the annual meeting date, and risk factor updates linked to strategic transactions.
Investors can also review definitive proxy statements on Schedule 14A, such as the document filed on September 15, 2025. That proxy statement outlines the agenda for the annual meeting of stockholders, including director elections, ratification of the independent registered public accounting firm, an amendment to the 2023 Equity Incentive Plan, and advisory votes on executive compensation and its frequency. It also describes corporate governance guidelines, board structure, director and executive compensation, and ownership information.
Through Stock Titan, these XTNT filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries designed to explain the main points in accessible language. Users can quickly see what each filing covers—such as divestiture terms, debt prepayments, equity plan changes, or non-GAAP metric definitions—without reading every page in full.
For those tracking financial performance and capital structure, the filings include condensed consolidated balance sheets, income statement data, and discussions of liquidity, debt arrangements, and credit facility consents. Governance-focused readers can examine voting results from the annual meeting, details of equity incentive plan amendments, and disclosures about significant shareholders and board composition.
By using this XTNT filings page, investors, analysts, and researchers can navigate Xtant Medical’s regulatory history, understand the implications of its asset sales and biologics-focused strategy, and interpret recurring topics such as non-GAAP adjusted EBITDA and risk factors, with AI tools helping to highlight the most important elements in each submission.